Clinical development of neridronate: potential for new applications
Received 31 January 2013
Accepted for publication 26 February 2013
Published 3 April 2013 Volume 2013:9 Pages 139—147
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Davide Gatti, Maurizio Rossini, Ombretta Viapiana, Luca Idolazzi, Silvano Adami
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Abstract: Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing a useful system for administration in homecare. In this review, we discuss the latest clinical results of neridronate administration in OI and PDB, as well as in osteoporosis and other conditions. We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I.
Keywords: bisphosphonates, osteogenesis imperfecta, osteoporosis, complex regional pain syndrome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.